Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

NCT07191717 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Invasive Breast Carcinoma
Localized Estrogen Receptor-Positive Breast Carcinoma
Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma

Interventions

DRUG: Abemaciclib
PROCEDURE: Biospecimen Collection
DRUG: Imlunestrant
OTHER: Questionnaire Administration
PROCEDURE: Radiologic Imaging Procedure

Sponsor

Jonsson Comprehensive Cancer Center